Brii Biosciences Presents Elebsiran Phase II Data at APASL 2025 Meeting
China-based Brii Biosciences Ltd (HKG: 2137) has published the latest data from its ongoing Phase...
Academic conference
InnoCare Pharma Presents Positive Phase II Results of ICP-488 in Psoriasis at AAD Meeting
China-based InnoCare Pharma (HKG: 9969, SHA: 688428) announced the oral presentation of results from the...
Sanofi and Teva’s Duvakitug Hits Key Milestones in UC and CD Study at ECCO Congress
Sanofi (EPA: SAN, NASDAQ: SNY) and Teva Pharmaceutical Industries Ltd (NYSE: TEVA) presented Phase IIb...
J&J’s Tremfya Meets All Endpoints in Phase III UC Study, Eyes FDA Approval for SC Induction
U.S. pharmaceutical giant Johnson & Johnson (J&J, NYSE: JNJ) presented positive results from the Phase...
Kelun-Biotech to Present SKB264/MK-2870 Data for Urothelial Carcinoma at ASCO-GU 2025
China’s Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) will present efficacy and safety data from...
Transcenta’s LIV-1 ADCs Show Promising Results in Pre-Clinical Breast Cancer Study
China-based biotech company Transcenta Holdings Ltd (HKG: 6628) announced updated results from a pre-clinical study...
Arvinas and Pfizer Present Positive TACTIVE-U Sub-Study Data at SABCS 2024
Partners Arvinas, Inc. (NASDAQ: ARVN) and Pfizer Inc. (NYSE: PFE) have jointly presented preliminary data...
Novartis’ Kisqali Shows Sustained Efficacy in NATALEE Study at SABCS 2024
Swiss pharmaceutical giant Novartis (NYSE: NVS) presented updated results from the pivotal Phase III NATALEE...
Legend Biotech’s Carvykti Demonstrates High MRD Negativity Rates in Phase III CARTITUDE-4 Trial
China-based Legend Biotech Corporation (NASDAQ: LEGN) has released new data on minimal residual disease (MRD)...
Wuhan YZY Biopharma’s M701 Shows Promise in Phase II Study for Malignant Pleural Effusion at ESMO ASIA 2024
China-based Wuhan YZY Biopharma Co., Ltd (HKG: 2496) has announced the presentation of results from...
Dizal Pharmaceutical Unveils Promising Data on DZD8586 for B-NHL at ASH Annual Meeting
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has presented new data from a pooled safety...
Eli Lilly’s Jaypirca Demonstrates Superiority in BRUIN CLL-321 Study for CLL/SLL Treatment
US pharmaceutical major Eli Lilly and Company (NYSE: LLY) unveiled the latest data from the...
Keymed Biosciences Presents CM336 Data for Relapsed Multiple Myeloma at ASH Annual Meeting
China-based Keymed Biosciences Inc., (HKG: 2162) has announced the presentation of the latest data from...
Antengene’s Xpovio Showcases Positive Results in Phase III BENCH and Phase I/II TOUCH Studies at ASH 2024
China-based Antengene Corporation Limited (Antengene, HKG: 6996) announced the presentation of the latest results from...
Amgen’s Blincyto Meets Primary Endpoint in Phase III AALL1731 Study for Pediatric B-ALL
US-based biotechnology company Amgen (NASDAQ: AMGN) has published the results from the Phase III study...
Johnson & Johnson’s Darzalex Faspro Showcases Clinical Efficacy in Multiple Myeloma at ASH 2024
US healthcare conglomerate Johnson & Johnson (J&J, NYSE: JNJ) has presented results from several clinical...
Duality Biologics’ BNT324/DB-1311 Shows Positive Results in Global Phase I/IIa Study at ESMO Asia
Duality Biologics, a developer of antibody conjugate drugs (ADCs) with operations in the United States...
Innovent Biologics’ IBI343 Shows Promising Results in Phase I Study for Pancreatic Cancer at ESMO Asia
China-based biopharmaceutical company Innovent Biologics, Inc. (HKG: 1801) presented updated data from the Phase I...
Novartis’ Scemblix Demonstrates Superior MMR Rates in Phase III ASC4FIRST Study
Swiss pharmaceutical giant Novartis (NYSE: NVS) unveiled longer-term results from the pivotal Phase III ASC4FIRST...
Tecvayli (Teclistamab) Demonstrates Positive Results in MajesTEC-5 and MajesTEC-4 Trials
Janssen-Cilag International NV, a subsidiary of US healthcare giant Johnson & Johnson (J&J; NYSE: JNJ),...